In gastrointestinal stromal tumors (GIST) and other cancer types, AXL overexpression has been associated with intrinsic or acquired resistance to targeted therapies, as well as to chemotherapy and radiotherapy [14,15,16,17]. Here, AXL is linked to gastrointestinal stromal tumor.